Company Interview / ausbiz Capital presenting partner

Marc Voight from Immutep shares insights on biotech's focus on leveraging patients' immune systems to fight diseases. Immutep's LAG-3 mechanism helps either upregulate or downregulate the immune response based on whether it's for cancer or autoimmune conditions, respectively.

Immutep is collaborating with Merck, utilising Keytruda in trials for non-small cell lung cancer.,Immutep's promising future involves a robust pipeline, including five key clinical programs. Immutep also partners with research institutions such as the Monash Institute, ensuring a strong network to support their strategic goals. The company has out-licensed some drugs to giants like Novartis, showcasing a proactive approach.

*The information contained in this event is general in nature and is not intended as advice. 

Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances. 

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD